How did NanoViricides' expenses impact its revenue in Q2 2025?

NanoViricides' expenses had a significant impact on its revenue in Q2 2025. The company's total revenue for the quarter was $0, which was largely due to the high level of expenses incurred during the period. 1. **Expenses Overview**: - Research and Development (R&D) expenses were expected to be between $8 million and $10 million. - Selling and administrative expenses were within the range of $23 million to $25 million. 2. **Revenue Impact**: - The company's revenue was significantly lower than the previous quarter's revenue of $132 million, indicating a substantial decline. - The decline in revenue can be attributed to the high expenses, which likely exceeded the revenue generated during the quarter. 3. **Financial Guidance**: Despite the challenging financial outlook, the company provided guidance for Q2 2025 with revenue expected to be between $135 million and $145 million. This suggests that the company is optimistic about future performance, possibly due to strategic adjustments or new initiatives. In conclusion, NanoViricides' expenses had a negative impact on its revenue in Q2 2025, with the company facing a challenging financial period. However, the guidance for the upcoming quarter indicates a potential recovery or improvement in the company's financial performance.